Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Subscribe To Our Newsletter & Stay Updated
